Johnson & Johnson’s (JNJ) “Buy” Rating Reaffirmed at Guggenheim

Johnson & Johnson (NYSE:JNJ)‘s stock had its “buy” rating reiterated by equities researchers at Guggenheim in a note issued to investors on Wednesday, MarketBeat.com reports. They currently have a $287.00 target price on the stock. Guggenheim’s price objective would suggest a potential upside of 9.85% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $287.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday. Argus set a $300.00 target price on Johnson & Johnson in a research report on Wednesday, July 29th. Bank of America reiterated a “neutral” rating and issued a $278.00 price objective on shares of Johnson & Johnson in a report on Tuesday, September 29th. Scotiabank reiterated an “outperform” rating and issued a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, TD Cowen upped their price target on Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $276.22.

Johnson & Johnson Price Performance

JNJ traded up $4.79 during trading on Wednesday, hitting $261.27. The company’s stock had a trading volume of 5,725,485 shares, compared to its average volume of 7,959,566. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The business’s fifty day simple moving average is $265.83 and its 200 day simple moving average is $249.01. The firm has a market capitalization of $629.64 billion, a price-to-earnings ratio of 30.27, a P/E/G ratio of 2.59 and a beta of 0.21. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business’s revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.3 EPS for the current fiscal year.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

Large investors have recently modified their holdings of the business. Outlook Capital Management LLC acquired a new stake in Johnson & Johnson during the 2nd quarter valued at $28,000. Matrix Trust Co boosted its holdings in Johnson & Johnson by 56.3% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after acquiring an additional 54 shares during the last quarter. Hyposwiss Advisors SA acquired a new position in Johnson & Johnson in the fourth quarter valued at $42,000. Montgomery Financial Services LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth about $43,000. Finally, Polaris Financial Partners acquired a new position in shares of Johnson & Johnson during the third quarter worth about $56,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported two-year Phase 3 ICONIC-LEAD results for ICOTYDE (icotrokinra), its targeted oral IL-23 receptor peptide for moderate-to-severe plaque psoriasis. Nearly three-quarters of adults and adolescents achieved clear or almost clear skin at two years, with responses sustained and a favorable safety profile. The results strengthen the potential of ICOTYDE as a future growth product and were presented at a dermatology meeting. Johnson & Johnson ICOTYDE two-year psoriasis data
• Positive Sentiment: Guggenheim reaffirmed a Buy rating, while Morgan Stanley also issued a Buy rating. The positive analyst view reflects JNJ’s diversified healthcare portfolio, drug launches and defensive dividend appeal. Guggenheim reaffirms Buy rating
• Positive Sentiment: Several investment commentaries continue to present JNJ as a dividend-focused healthcare holding, emphasizing its long record of dividend growth and relatively dependable cash generation compared with higher-yielding but riskier peers. Healthcare Dividend Aristocrats
• Neutral Sentiment: JNJ is approaching its third-quarter earnings report with expectations for continued strength in pharmaceuticals and newer product launches. Investors will focus on revenue growth, guidance and the pace of Stelara-related sales erosion.
• Negative Sentiment: Analysts warn that biosimilar competition for Stelara and challenges in the MedTech business could weigh on near-term growth, limiting the impact of otherwise strong drug performance. J&J stock ahead of Q3 earnings
• Negative Sentiment: Upcoming patent expirations for Imbruvica and Darzalex create a longer-term “patent cliff” risk, potentially pressuring pharmaceutical revenue unless pipeline products and acquisitions offset lost exclusivity. J&J patent cliff analysis
• Negative Sentiment: Boston Scientific has sued JNJ subsidiary Atraverse over alleged patent infringement involving the Hotwire cardiology device, seeking damages and an injunction. The financial impact is uncertain but adds legal and competitive risk to the MedTech segment. Boston patent lawsuit against J&J subsidiary

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.